Tilray Brands, Inc.

TLRY Healthcare Drug Manufacturers Specialty & Generic

Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.04 0.17 −5.30%
Market cap
$474.4M
P/E
0.0×
Fwd P/E
−14.8×
Dividend yield
—
F-score
3/9
Altman Z
−1.96
Beneish M
−2.01
Dividend safety
n/a
Older periods Nov '25 Feb '26 May '26 Aug '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.03 1.00 0.67 0.63
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(100.82) (39.03) (16.45) (36.84)
P/B ratio
0.56 0.56 0.39 0.38
EV/Sales
1.04 1.04 0.83 0.77
EV/EBITDA
0.00 0.00 60.51 0.00
EV/FCF
(8.58) (6.95) (4.81) (4.24)
Current Ratio
2.81 2.79 2.21 1.88
Net Debt/EBITDA
(2.79) (2.66) 13.11 (32.90)
Debt/Equity
0.20 0.20 0.24 0.22
Earnings Yield
(283.46%) (179.61%) (19.67%) (30.20%)
Free Cash Flow Yield
(11.81%) (14.99%) (25.61%) (28.63%)
Free Cash Flow per Share
(0.16) (0.21) (0.61) (0.21)
Book value per Share
14.02 13.54 14.26 12.05
Free Cash Flow
(18.10) (24.19) (68.60) (27.45)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 13 Oct 2026